多発性硬化症治療薬の世界市場レポート 2025年

多発性硬化症治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.1％で479億7,000万米ドルに成長します。予測期間の成長は、臨床試験の利用可能性の増加、標的治療、予防医学への注目の高まり、バイオシミラーへの需要の高まり、地理的範囲の拡大、併用療法などに起因すると考えられます。予測期間における主な動向には、免疫調節薬や免疫調節薬、長時間作用型製剤、患者中心の医療、薬剤革新、経口療法や輸液療法などがあります。

政府や非政府組織は多発性硬化症治療薬市場の成長に大きく貢献しています。これらの団体は、多発性硬化症（MS）に罹患した人々の生活の質の向上を目的とした様々なプログラムやイニシアチブを支援しています。一例として、アルバータ州政府とカナダ経済開発・貿易・観光省が、Canadian Prospective Cohort Study on MS（CanProCo）のために100万米ドルを共同投資したことが挙げられます。複数の組織が支援するこのイニシアチブには、研究とイノベーションのために1,000万米ドルが集まり、カナダ国内の約50人のMS研究者が分野を超えて結集しました。このような団体からの資金援助が、多発性硬化症治療薬市場の拡大を後押ししています。

多発性硬化症の有病率の上昇は、多発性硬化症治療薬市場の成長を推進する極めて重要な要因です。MSは中枢神経系に影響を及ぼす自己免疫疾患であり、症状管理と疾患進行のために医薬品の介入が必要です。2023年5月のPace Hospitalsの記事によると、世界のMS患者数は280万人で、10万人当たり35.9人の割合であり、75の報告国で10万人当たり2.1人の年間発症率です。この病気は通常32歳前後で発症し、女性の有病率が高いです。このような有病率の増加は、多発性硬化症治療薬市場の拡大の原動力となると思われます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多発性硬化症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の多発性硬化症治療薬市場：成長率分析
• 世界の多発性硬化症治療薬市場の実績：規模と成長, 2019-2024
• 世界の多発性硬化症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界多発性硬化症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多発性硬化症治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節薬
• 免疫抑制剤
• インターフェロン
• その他の薬物クラス
• 世界の多発性硬化症治療薬市場流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンラインストア
• 世界の多発性硬化症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口薬
• 非経口薬
• 世界の多発性硬化症治療薬市場免疫調節剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• グラチラマー酢酸塩
• フィンゴリモド
• テリフルノミド
• ジメチルフマル酸
• 世界の多発性硬化症治療薬市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナタリズマブ
• アレムツズマブ
• オクレリズマブ
• 世界の多発性硬化症治療薬市場インターフェロンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インターフェロンβ-1a
• インターフェロンベータ1b
• 世界の多発性硬化症治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• スフィンゴシン1リン酸受容体モジュレーター
• モノクローナル抗体
• その他の新興治療法

第7章 地域別・国別分析

• 世界の多発性硬化症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多発性硬化症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発性硬化症治療薬市場：競合情勢
• 多発性硬化症治療薬市場：企業プロファイル
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer HealthCare LLC Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck & Co. Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Acorda Therapeutics Inc.
• Actelion Pharmaceuticals Ltd
• EMD Serono Inc.
• AbbVie Inc.
• Bayer Schering Pharma AG
• CinnoVex
• Rebif
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Mallinckrodt Pharmaceuticals
• Mitsubishi Tanabe Pharma Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多発性硬化症治療薬市場2029：新たな機会を提供する国
• 多発性硬化症治療薬市場2029：新たな機会を提供するセグメント
• 多発性硬化症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Multiple sclerosis drugs, referred to as disease-modifying treatments, aim to halt the progression of disability and the occurrence of disease relapses associated with the condition. These medications work by targeting a protein present on the surface of immune cells, leading to a reduction in the number of white blood cells. This reduction helps prevent relapses in multiple sclerosis by potentially diminishing the white blood cells' tendency to cause nerve injury.

The primary drug classes for multiple sclerosis treatment include immunomodulators, immunosuppressants, interferons, and others. Immunomodulators specifically target pathways involved in treating multiple myeloma and certain other cancers. These drugs can be administered through various routes, including oral and parenteral methods, and are distributed through hospital pharmacies, retail pharmacies, and online platforms.

The multiple sclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple sclerosis drugs market size has grown strongly in recent years. It will grow from $29.66 billion in 2024 to $31.5 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of multiple sclerosis, unmet medical need, rising investments from pharmaceuticals, growing awareness of multiple sclerosis.

The multiple sclerosis drugs market size is expected to see rapid growth in the next few years. It will grow to $47.97 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing availability of clinical trials, targeted therapy, growing focus on preventive medicine, growing demand for biosimilars, expanding geographical reach, combination therapies. Major trends in the forecast period include immunomodulatory and immunomodulatory drugs, long-acting formulations, patient-centric care, drug innovation, oral and infusion therapies.

Government and non-government organizations contribute significantly to the growth of the multiple sclerosis drugs market. They support various programs and initiatives aimed at improving the quality of life for those affected by multiple sclerosis (MS). An example is the joint investment of $1 million by the government of Alberta and Canada's Department of Economic Development, Trade, and Tourism for the Canadian Prospective Cohort Study on MS (CanProCo). This initiative, supported by multiple organizations, gathered $10 million for research and innovations, uniting nearly 50 MS researchers across disciplines in Canada. Financial backing from these entities drives the expansion of the multiple sclerosis drugs market.

The escalating prevalence of multiple sclerosis stands as a pivotal factor propelling the growth of the multiple sclerosis drug market. MS, an autoimmune disease impacting the central nervous system, requires pharmaceutical intervention for symptom management and disease progression. An article from Pace Hospitals in May 2023 highlighted a global MS patient count of 2.8 million, at a rate of 35.9 per 100,000 individuals, with an annual incidence of 2.1 cases per 100,000 people across 75 reporting countries. The disease typically affects individuals around the age of 32 and shows a higher prevalence among females. This increasing prevalence is set to drive the expansion of the multiple sclerosis drug market.

Companies are intensifying efforts to introduce new products within the multiple sclerosis drug market to cater to the surging demand. Given the lifelong treatment nature of MS, the overall cost of patient care is substantial. To address this, companies are focusing on developing specific drugs tailored for managing multiple sclerosis. Notably, the FDA approved Novartis' Mayzent (siponimod) and EMD Serono's Mavenclad (cladribine) for treating relapsing-remitting and active secondary progressive multiple sclerosis. These oral drugs aim to provide more effective treatment options.

Major companies in the multiple sclerosis drugs market are concentrating on developing innovative solutions to enhance treatment effectiveness, improve patient quality of life, and meet the diverse needs of individuals living with multiple sclerosis. Innovative solutions encompass new and creative approaches, products, or technologies aimed at effectively tackling specific challenges or issues. For example, in September 2024, Genentech, a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only subcutaneous injection, administered by healthcare professionals, that is given twice a year and takes about 10 minutes to administer, providing additional treatment options for individuals with MS.

In March 2024, Juvise Pharmaceuticals, a pharmaceutical company based in France, acquired Actelion Pharmaceuticals Ltd. for an undisclosed sum. This acquisition aims to broaden Juvise Pharmaceuticals' portfolio and improve patient care by obtaining global commercial rights to Ponvory for treating relapsing multiple sclerosis outside the US and Canada. Actelion Pharmaceuticals Ltd. is a pharmaceutical company located in Switzerland, specializing in the discovery, development, and commercialization of innovative drugs.

Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd, EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

North America was the largest region in the global multiple sclerosis drug market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Sclerosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple sclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple sclerosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple sclerosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Other Drug Classes
• 2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores
• 3) By Route Of Administration: Oral Drugs; Parenteral Drugs
• Subsegments:
• 1) By Immunomodulators: Glatiramer Acetate; Fingolimod; Teriflunomide; Dimethyl Fumarate
• 2) By Immunosuppressants: Natalizumab; Alemtuzumab; Ocrelizumab
• 3) By Interferons: Interferon Beta-1a; Interferon Beta-1b
• 4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators; Monoclonal Antibodies; Other Emerging Therapies
• Companies Mentioned: Biogen Inc.; Novartis International AG; F. Hoffmann-La Roche Ltd.; Bayer HealthCare LLC; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multiple Sclerosis Drugs Market Characteristics

3. Multiple Sclerosis Drugs Market Trends And Strategies

4. Multiple Sclerosis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Multiple Sclerosis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multiple Sclerosis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multiple Sclerosis Drugs Market Growth Rate Analysis
• 5.4. Global Multiple Sclerosis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multiple Sclerosis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multiple Sclerosis Drugs Total Addressable Market (TAM)

6. Multiple Sclerosis Drugs Market Segmentation

• 6.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulators
• Immunosuppressants
• Interferons
• Other Drug Classes
• 6.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Stores
• 6.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Drugs
• Parenteral Drugs
• 6.4. Global Multiple Sclerosis Drugs Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glatiramer Acetate
• Fingolimod
• Teriflunomide
• Dimethyl Fumarate
• 6.5. Global Multiple Sclerosis Drugs Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natalizumab
• Alemtuzumab
• Ocrelizumab
• 6.6. Global Multiple Sclerosis Drugs Market, Sub-Segmentation Of Interferons, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon Beta-1a
• Interferon Beta-1b
• 6.7. Global Multiple Sclerosis Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sphingosine 1-Phosphate Receptor Modulators
• Monoclonal Antibodies
• Other Emerging Therapies

7. Multiple Sclerosis Drugs Market Regional And Country Analysis

• 7.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multiple Sclerosis Drugs Market

• 8.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multiple Sclerosis Drugs Market

• 9.1. China Multiple Sclerosis Drugs Market Overview
• 9.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multiple Sclerosis Drugs Market

• 10.1. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multiple Sclerosis Drugs Market

• 11.1. Japan Multiple Sclerosis Drugs Market Overview
• 11.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multiple Sclerosis Drugs Market

• 12.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multiple Sclerosis Drugs Market

• 13.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multiple Sclerosis Drugs Market

• 14.1. South Korea Multiple Sclerosis Drugs Market Overview
• 14.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multiple Sclerosis Drugs Market

• 15.1. Western Europe Multiple Sclerosis Drugs Market Overview
• 15.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multiple Sclerosis Drugs Market

• 16.1. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multiple Sclerosis Drugs Market

• 17.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multiple Sclerosis Drugs Market

• 18.1. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multiple Sclerosis Drugs Market

• 19.1. Italy Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multiple Sclerosis Drugs Market

• 20.1. Spain Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multiple Sclerosis Drugs Market

• 21.1. Eastern Europe Multiple Sclerosis Drugs Market Overview
• 21.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multiple Sclerosis Drugs Market

• 22.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multiple Sclerosis Drugs Market

• 23.1. North America Multiple Sclerosis Drugs Market Overview
• 23.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multiple Sclerosis Drugs Market

• 24.1. USA Multiple Sclerosis Drugs Market Overview
• 24.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multiple Sclerosis Drugs Market

• 25.1. Canada Multiple Sclerosis Drugs Market Overview
• 25.2. Canada Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multiple Sclerosis Drugs Market

• 26.1. South America Multiple Sclerosis Drugs Market Overview
• 26.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multiple Sclerosis Drugs Market

• 27.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multiple Sclerosis Drugs Market

• 28.1. Middle East Multiple Sclerosis Drugs Market Overview
• 28.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multiple Sclerosis Drugs Market

• 29.1. Africa Multiple Sclerosis Drugs Market Overview
• 29.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Multiple Sclerosis Drugs Market Competitive Landscape
• 30.2. Multiple Sclerosis Drugs Market Company Profiles
  • 30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer HealthCare LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Multiple Sclerosis Drugs Market Other Major And Innovative Companies

• 31.1. Merck & Co. Inc.
• 31.2. Sanofi S.A.
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. GlaxoSmithKline plc
• 31.5. Acorda Therapeutics Inc.
• 31.6. Actelion Pharmaceuticals Ltd
• 31.7. EMD Serono Inc.
• 31.8. AbbVie Inc.
• 31.9. Bayer Schering Pharma AG
• 31.10. CinnoVex
• 31.11. Rebif
• 31.12. Bristol-Myers Squibb Company
• 31.13. Johnson & Johnson
• 31.14. Mallinckrodt Pharmaceuticals
• 31.15. Mitsubishi Tanabe Pharma Corporation

32. Global Multiple Sclerosis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

34. Recent Developments In The Multiple Sclerosis Drugs Market

35. Multiple Sclerosis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Multiple Sclerosis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multiple Sclerosis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multiple Sclerosis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer